Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey

BACKGROUND: Understanding how patients perceive the efficacy, safety, and administrative burden of treatments for metastatic castration‐resistant prostate cancer (mCRPC) can facilitate shared‐decision making for optimal management. This study sought to elicit patient preferences for mCRPC treatments...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Daniel J., Mohamed, Ateesha F., Tsai, Jui‐Hua, Karimi, Milad, Ning, Ning, Jayade, Sayeli, Botteman, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028042/
https://www.ncbi.nlm.nih.gov/pubmed/36226867
http://dx.doi.org/10.1002/cam4.5313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028042/
https://www.ncbi.nlm.nih.gov/pubmed/36226867
http://dx.doi.org/10.1002/cam4.5313

Ejemplares similares